Quantcast

Advanced Viral Receives Notice of Allowance for Patents

July 14, 2008

Advanced Viral Research Corp. (OTCBB: ADVR), a cancer therapeutics company, announced today that it has received two Notices of Allowance for patents related to alleviating side effects in patients undergoing treatments for cancer.

The first Notice of Allowance is from the U.S. Patent Office for a method to reduce side effects in cancer patients undergoing chemotherapy. The second Notice of Allowance is from the Canadian Patent Office for treating anemia in cancer patients undergoing chemotherapy or radiotherapy, or suffering from chronic renal failure.

These Notices of Allowances continue to strengthen ADVR’s portfolio patent position in treating cancer-related symptoms with its lead product AVR118. AVR118 is currently undergoing a Phase II study for alleviating the symptoms of clinical cachexia, such as anorexia, fatigue and weight loss, in cancer patients.

Stephen M. Elliston, President and CEO of Advanced Viral Research, stated, “Few drugs are available to effectively treat cachexia symptoms, and there is clearly a large market with a critical need for such therapies. It is important to develop drugs to treat the symptoms of clinical cachexia to improve quality of life and help patients to better tolerate the treatment regimens.”

About Advanced Viral Research Corp.

Advanced Viral Research Corp. is a biopharmaceutical company dedicated to the discovery and development of small molecule anti-cancer drugs. Its initial compounds, AVR118 and AVR123, represent a new class of cytoprotective agent that targets, among other things, some of the most problematic symptoms associated with clinical cachexia or the so called wasting syndrome. In addition, AVR118 and AVR123 have also been shown to possess topical wound healing properties in animal models. Various degenerative conditions associated with cachexia such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 and AVR123 therapies. For further information regarding Advanced Viral Research Corp., please visit the website at http://www.adviral.com.

This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 and AVR123 are not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue operations and/or complete the clinical trials of AVR118 or AVR123, or satisfy certain other conditions relating to clinical trials or that if the trials are completed, this will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

 Contact: Grayling Global Mounir Ibrahim 646-284-9474 mibrahim@hfgcg.com

SOURCE: Advanced Viral Research Corp.




comments powered by Disqus